首页> 美国卫生研究院文献>Multiple Sclerosis International >Outcome Measures in Relapsing-Remitting Multiple Sclerosis: Capturing Disability and Disease Progression in Clinical Trials
【2h】

Outcome Measures in Relapsing-Remitting Multiple Sclerosis: Capturing Disability and Disease Progression in Clinical Trials

机译:复发-缓解型多发性硬化的结果指标:在临床试验中捕获残疾和疾病进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease that manifests as acute relapses and progressive disability. As a primary endpoint for clinical trials in MS, disability is difficult to both characterize and measure. Furthermore, the recovery from relapses and the rate of disability vary considerably among patients. Given these challenges, investigators have developed and studied the performance of various outcome measures and surrogate endpoints in MS clinical trials. This review defines the outcome measures and surrogate endpoints used to date in MS clinical trials and presents challenges in the design of both adult and pediatric trials.
机译:多发性硬化症(MS)是一种慢性炎症和神经退行性疾病,表现为急性复发和进行性残疾。作为MS临床试验的主要终点,残疾既难以表征也无法测量。此外,患者的复发恢复和残障率差异很大。面对这些挑战,研究人员已经开发并研究了各种临床疗效指标和替代终点的性能。这篇综述定义了迄今为止在MS临床试验中使用的结局指标和替代终点,并提出了成人和儿科试验设计中的挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号